CRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CorMedix Inc (CRMD) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock exhibits mixed signals, with no strong technical or proprietary trading signals, and its financial performance shows significant challenges despite revenue growth. While upcoming clinical data could act as a catalyst, the lack of recent insider or institutional buying and reduced analyst price targets suggest caution. Holding off on buying until more clarity on clinical results and financial improvement is advised.
The MACD is positive but contracting, RSI is neutral at 36.983, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 7.366), but the lack of momentum suggests limited upside potential in the short term.
Upcoming clinical data could act as a significant catalyst for the stock, potentially driving investor interest and stock price increases if results are favorable.
Reduced analyst price targets and guidance for FY26 and FY27 revenue significantly below initial estimates. Financial performance shows a steep decline in net income, EPS, and gross margin. No recent insider or institutional buying activity.
In 2025/Q3, revenue increased by 810.22% YoY to $104.28M, but net income dropped by -4009.63% YoY to -$108.56M. EPS fell by -2620% YoY to 1.26, and gross margin declined by -5.05% YoY to 89.26%. This indicates significant financial challenges despite revenue growth.
Analysts have lowered price targets recently (H.C. Wainwright: $13 from $18, RBC Capital: $13 from $22, Truist: $16 from $20) but maintain Buy or Outperform ratings. This reflects cautious optimism but highlights concerns over future revenue and clinical execution.
